BioDrugs

, Volume 21, Issue 2, pp 135–137 | Cite as

Panitumumab in the Treatment of Metastatic Colorectal Cancer

Profile Report
  • Sheridan M. Hoy
  • Antona J. Wagstaff
Adis Profile Report

Keywords

Epidermal Growth Factor Receptor Irinotecan Cetuximab Metastatic Colorectal Cancer Epidermal Growth Factor Receptor Expression 

References

  1. 1.
    Hoy SM, Wagstaff AJ. Panitumumab: in the treatment of metastatic colorectal cancer. Drugs 2006; 66(15): 2005–14PubMedCrossRefGoogle Scholar
  2. 2.
    Malik I. Panitumumab: a viewpoint by Imtiaz Malik. Drugs 2006; 66(15): 2015CrossRefGoogle Scholar
  3. 3.
    Ranson M. Panitumumab: a viewpoint by Malcolm Ranson. Drugs 2006; 66(15): 2015–6CrossRefGoogle Scholar
  4. 4.
    World Health Organization. Cancer [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs297/en/print.html [Accessed 2006 May 18]
  5. 5.
    Labianca RF, Beretta GD, Pessi MA. Colorectal cancer: disease management considerations. Drugs 2001; 61(12): 1751–64PubMedCrossRefGoogle Scholar
  6. 6.
    Jefford M, Zalcberg J. Recent advances in the systemic therapy of metastatic colorectal cancer. Am J Cancer 2005; 4(1): 15–34CrossRefGoogle Scholar
  7. 7.
    Coutinho AK, Rocha Lima CMS. Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 2003; 10(3): 224–38PubMedGoogle Scholar
  8. 8.
    Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000 Sep 2; 321(7260): 531–5PubMedCrossRefGoogle Scholar
  9. 9.
    Alekshun T, Garrett C. Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005 Apr; 12(2): 105–10PubMedGoogle Scholar
  10. 10.
    Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103(12): 2435–46PubMedCrossRefGoogle Scholar
  11. 11.
    McWilliams RR, Erlichman C. Novel therapeutics in colorectal cancer. Dis Colon Rectum 2005; 48(8): 1632–50PubMedCrossRefGoogle Scholar
  12. 12.
    Ranson M. Technology evaluation: ABX-EGF, Abgenix/Amgen. Curr Opin Mol Ther 2003 Oct; 5(5): 541–6PubMedGoogle Scholar
  13. 13.
    Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004 Dec; 11(4): 689–708PubMedCrossRefGoogle Scholar
  14. 14.
    Veronese ML, O’Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004 Jun; 40(9): 1292–301PubMedCrossRefGoogle Scholar
  15. 15.
    Levene AP, Singh G, Palmieri C. Therapeutic monoclonal antibodies in oncology. J R Soc Med 2005; 98(4): 146–52PubMedCrossRefGoogle Scholar
  16. 16.
    Yang X-D, Jia X-C, Corvalan JRF, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17–23PubMedCrossRefGoogle Scholar
  17. 17.
    Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006 Jan-Feb; 29(1): 1–9PubMedCrossRefGoogle Scholar
  18. 18.
    Peeters M, Van Custem E, Siena S, et al. A phase III, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer [abstract no. CP-1] plus oral presentation at 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1-5; Washington, DCGoogle Scholar
  19. 19.
    Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr) [abstract no. 3548]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 158s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2–6; Atlanta (GA)Google Scholar
  20. 20.
    Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (<l–9%) or negative (<1 %) levels of epidermal growth factor receptor (EGFr) [abstract no. 3547]. J Clin Oncol 2006; 24 (18 Suppl. Pt 1): 157s. Plus poster presented at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting; 2006 Jun 2–6; Atlanta (GA)CrossRefGoogle Scholar
  21. 21.
    Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer [abstract no. 3520]. J Clin Oncol 2005; 23 (16 Suppl. Pt I): 251S. Plus poster presented at the 41st American Society of Clinical Oncology (ASCO) Annual Meeting; 2005 May 13–17; Orlando (FL)Google Scholar
  22. 22.
    Hecht J, Posey S, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan or FOLFIRI for first-line treatment of metastatic colorectal cancer [abstract no. 237]. 3rd Annual Gastrointestinal Cancers Symposium; 2006 Jan 26–28; San Francisco (CA)Google Scholar
  23. 23.
    Amgen. Vectibix™ [panitumumab] prescribing information [online]. Available from URL: http://www.fda.gov/ [Accessed 2006 Oct 3]

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Sheridan M. Hoy
    • 1
    • 2
  • Antona J. Wagstaff
    • 1
    • 2
  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations